Inhibition of rBet v 1‐induced basophil histamine release with specific immunotherapy ‐induced serum immunoglobulin G: no evidence that FcγRIIB signalling is important

Ejrnaes, Anne M; Svenson, Morten; Lund, G.; Larsen, Jørgen Nedergaard; Jacobi, Henrik H.

doi:10.1111/j.1365-2222.2006.02442.x

Cited by 53 publications

(48 citation statements)

References 46 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been reported that concomitant binding of IgG and IgE antibodies to the same allergen may down-regulate effector cell responses through co-cross-linking of IgE and IgG receptors (Malbec and Daeron 2007;Mertsching et al 2008). These studies have been performed mainly in murine models whereas for human immunotherapy studies no evidence for down-regulation of effector cell activation by co-cross-linking has been found so far (Ejrnaes et al 2006). Moreover, allergen-specific IgG antibodies are responsible for the reduction of IgE-facilitated antigen presentation by preventing the binding of allergen to APCbound IgE antibodies resulting in decreased T cell activation.…”

Section: Beneficial Role Of Allergen-specific Blocking Igg Antibodiesmentioning

confidence: 98%

Passive Immunization with Allergen-Specific Antibodies

Flicker

Gadermaier

Madritsch

et al. 2011

Vaccines Against Allergies

View full text Add to dashboard Cite

The induction of allergen-specific IgG antibodies has been identified as a major mechanism responsible for the reduction of allergic inflammation in allergic patients treated by allergen-specific immunotherapy. Several studies suggest that allergen-specific IgG antibodies induced by vaccination with allergens block mast cell and basophil degranulation, IgE-facilitated allergen presentation to T cells and IgE production. The availability of recombinant allergens and technologies for the production of recombinant human antibodies allows engineering of allergen-specific antibodies which can be used for passive immunization (i.e., therapy) and eventually for the prevention of allergy (i.e., prophylaxis). This chapter summarizes data supporting the possible use of allergen-specific antibodies for treatment and prophylaxis. Finally, concrete approaches for the treatment and prevention of allergy based on blocking antibodies are envisioned.

show abstract

Section: Beneficial Role Of Allergen-specific Blocking Igg Antibodiesmentioning

confidence: 98%

Passive Immunization with Allergen-Specific Antibodies

Flicker

Gadermaier

Madritsch

et al. 2011

Vaccines Against Allergies

View full text Add to dashboard Cite

show abstract

“…The inhibitory effect of the BF may be mediated by antibodies (sIgG, sIgG4 or sIgA) and several authors have demonstrated that IgG or IgG4 contained in sera taken from patients under VIT showed an inhibitory activity on the basophil response [35]. …”

Section: Discussionmentioning

confidence: 99%

Follow-Up of Venom Immunotherapy on Flow Cytometry and Definition of a Protective Index

Sainte-Laudy

Touraine²,

Cluzan³

et al. 2016

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: A major problem of venom-specific immunotherapy (VIT) is the absence of reliable parameters for deciding treatment discontinuation. Aim of the Study: Intracutaneous tests (ICTs), the basophil activation test (BAT), specific IgEs (sIgEs) and blocking factor (BF) activity were measured during VIT. We made an evaluation by means of a protective index (PI) including ICT, BAT and BF values. Material and Methods: A population of 45 patients who had experienced a systemic reaction after an insect sting were tested before VIT (T0), at 1 week (T1w), at 10 weeks (T10w) and at 21 weeks (T21w), and, for a subgroup of 17 patients, at 3-5 years (T3-5y). Basophil activation (expressed in % CD63 and in the area under the curve) and BF activity were measured by flow cytometry using the CCR3/CD63 protocol. Results: The first 21 weeks of follow-up showed no significant variation in the ICT, sIgE and BAT measurements, except for BAT, by eliminating weak negative anti-IgE responses. In these conditions, the decrease in basophil activation was significant at T10w (p = 0.009) and T21w (p = 0.009). Increased BF activity was also significant at T10w (p = 0.008) and T21w (p = 0.002). The PI threshold calculated from the mean ± 3 standard errors (SE) was 64.8 (14.7 ± 16.7, n = 25) at T0. PI increase was significant at T3-5y (3,430 ± 6,282; p < 0.001). Conclusion: VIT induced a significant decrease in ICT values and basophil activation, along with an increase in serum BF activity, significant after 10 weeks of VIT. Evaluated in a larger population, the PI could represent a new tool for the clinico-biological follow-up of VIT efficacy.

show abstract

“…The inhibition could be caused by a direct inhibition of the allergen-IgE interaction or through coaggregation of the inhibitory FcγRIIB and FcεRI as demonstrated in an artificial system by Kepley et al [110]. However using sera from SIT-treated patients, we were not able to demonstrate a contribution of FcγRIIB activation to the inhibitory effect of SIT-induced IgG [111]. …”

Section: Inhibition Of Basophil/mast Cell Degranulation By Blocking Amentioning

confidence: 99%

IgE-Mediated Allergen Presentation and Blocking Antibodies: Regulation of T-Cell Activation in Allergy

Neerven

Knol

Ejrnaes

et al. 2006

Int Arch Allergy Immunol

116

View full text Add to dashboard Cite

It is well established that both the production of IgE by B lymphocytes and the maturation and recruitment of eosinophils in late-phase reactions are dependent on the activation of allergen-specific type-2 T-helper cells. What is less well known is the fact that efficient activation of allergen-specific T cells upon low-dose exposure to allergens is critically dependent on IgE-mediated or -facilitated allergen presentation. In fact, changes in the level of IgE-mediated allergen presentation may account for many of the immunological effects described for specific immunotherapy or anti-IgE treatment. This review aims to summarize the current knowledge, and will discuss the clinical relevance of blocking IgG antibodies induced by specific immunotherapy and anti-IgE monoclonal antibodies that both interfere with IgE-mediated allergen presentation.

show abstract

Inhibition of rBet v 1‐induced basophil histamine release with specific immunotherapy ‐induced serum immunoglobulin G: no evidence that FcγRIIB signalling is important

Cited by 53 publications

References 46 publications

Passive Immunization with Allergen-Specific Antibodies

Passive Immunization with Allergen-Specific Antibodies

Follow-Up of Venom Immunotherapy on Flow Cytometry and Definition of a Protective Index

IgE-Mediated Allergen Presentation and Blocking Antibodies: Regulation of T-Cell Activation in Allergy

Contact Info

Product

Resources

About